aTyr Pharma
ATYR
41 hedge funds and large institutions have $105M invested in aTyr Pharma in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 12 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.36% less ownership
Funds ownership: 73.97% → 70.6% (-3.4%)
13% less funds holding
Funds holding: 47 → 41 (-6)
32% less capital invested
Capital invested by funds: $154M → $105M (-$48.5M)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
63% less call options, than puts
Call options by funds: $445K | Put options by funds: $1.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TM
Tikvah Management
Charlotte,
North Carolina
|
+$708K |
| 2 |
TI
Telemetry Investments
New York
|
+$599K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$486K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$431K |
| 5 |
State Street
Boston,
Massachusetts
|
+$152K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$1.89M |
| 2 |
Two Sigma Investments
New York
|
-$1.43M |
| 3 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.14M |
| 4 |
Two Sigma Advisers
New York
|
-$1.08M |
| 5 |
VA
VR Adviser
New York
|
-$941K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BAM
51
Blueshift Asset Management
Red Bank,
New Jersey
| – | -$95K | -12,729 | Closed |
|
52
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$87K | -11,665 | Closed |
|
|
CG
53
Cutler Group
San Francisco,
California
| – | -$15.6K | -2,758 | -97% |
|
ATYR Hedge Fund Activity: Q1 2022 in Review
41 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2022, worth a combined $105M — down 32% from $154M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ATYR and 6 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 13 added.
The largest buyer was Tikvah Management, adding an estimated $708K. The largest seller was EAM Investors, exiting entirely with an estimated $1.89M sold.
- 41 institutional investors held aTyr Pharma (ATYR) as of Q1 2022, down from 47 in Q4 2021.
- Funds reported $105M of aTyr Pharma stock for Q1 2022, down 32% quarter-over-quarter.
- 6 funds opened new aTyr Pharma positions in Q1 2022 and 12 closed out, a net change of -6 holders.
- The largest aTyr Pharma buyer in Q1 2022 was Tikvah Management, an estimated $708K added.
- The largest aTyr Pharma seller in Q1 2022 was EAM Investors, an estimated $1.89M sold.
Based on aggregated 13F filings for Q1 2022.